- Home
- AKBA vs ZNTL Comparison
AKBA vs ZNTL Comparison
Compare AKBA & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- ZNTL
- Stock Information
- Founded
- AKBA 2007
- ZNTL 2014
- Country
- AKBA United States
- ZNTL United States
- Employees
- AKBA N/A
- ZNTL N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- AKBA Health Care
- ZNTL Health Care
- Exchange
- AKBA Nasdaq
- ZNTL Nasdaq
- Market Cap
- AKBA 958.6M
- ZNTL 105.8M
- IPO Year
- AKBA 2014
- ZNTL 2020
- Fundamental
- Price
- AKBA $3.93
- ZNTL $1.33
- Analyst Decision
- AKBA Strong Buy
- ZNTL Buy
- Analyst Count
- AKBA 5
- ZNTL 7
- Target Price
- AKBA $6.90
- ZNTL $8.60
- AVG Volume (30 Days)
- AKBA 4.4M
- ZNTL 1.4M
- Earning Date
- AKBA 08-07-2025
- ZNTL 08-08-2025
- Dividend Yield
- AKBA N/A
- ZNTL N/A
- EPS Growth
- AKBA N/A
- ZNTL N/A
- EPS
- AKBA N/A
- ZNTL N/A
- Revenue
- AKBA $184,909,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- AKBA $26.88
- ZNTL N/A
- Revenue Next Year
- AKBA $44.34
- ZNTL N/A
- P/E Ratio
- AKBA N/A
- ZNTL N/A
- Revenue Growth
- AKBA N/A
- ZNTL N/A
- 52 Week Low
- AKBA $1.07
- ZNTL $1.01
- 52 Week High
- AKBA $4.08
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- AKBA 67.02
- ZNTL 50.91
- Support Level
- AKBA $3.48
- ZNTL $1.15
- Resistance Level
- AKBA $3.77
- ZNTL $1.38
- Average True Range (ATR)
- AKBA 0.18
- ZNTL 0.10
- MACD
- AKBA -0.00
- ZNTL 0.01
- Stochastic Oscillator
- AKBA 75.16
- ZNTL 75.00
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.